CAMBRIDGE, Mass.: ConcertAI, a leading provider of multi-modal data and agentic AI solutions for life sciences and healthcare, today announced the appointment of Casey Graves as general manager of Clinical Solutions. In this pivotal role, Graves will drive growth and innovation in real-world data (RWD) and AI solutions for oncology research and clinical care, accelerating advances that improve outcomes for patients and healthcare providers.

As general manager, Graves will oversee the strategic direction of the oncology business, leading cross-functional teams in product development, data science, clinical operations, and commercial strategy. He will drive partnerships across the oncology ecosystem, leveraging ConcertAI’s data assets and AI capabilities to deliver impactful solutions for cancer research and care. Additionally, he’ll lead the CancerLinQ® initiative, solidifying ConcertAI’s leadership in oncology innovation.

Graves brings extensive experience in healthcare AI, analytics, and SaaS from leadership roles at major health technology and consulting firms. Most recently, he served as a board advisor and consultant for healthcare AI software companies. Prior to that, Graves was the general manager of Truven, the Health Insights and MarketScan businesses, at Merative, where he owned a profit and loss (P&L) of over $200M and executed successful growth and product modernization strategies during the transition from IBM Watson Health. He also held several general manager positions at IBM Watson Health, leading provider-focused business units and driving modernization and expansion. Before his time at IBM, Graves served as a partner at Deloitte Consulting, where he launched AI solutions for early adopter health systems, co-founded the Innovation Lab, and led the Healthcare Analytics Practice.

"Casey’s proven leadership in scaling healthcare SaaS solutions and his deep expertise in AI and analytics are a tremendous asset to our team," said Eron Kelly, CEO of ConcertAI. "As the general manager of our newly created and combined business unit overseeing RWE, Clinical Trials, and CancerLinQ, Casey steps into a vital leadership role. Casey’s vision and experience will be invaluable as we continue to enhance these offerings to deliver even greater impact for oncology care teams and the patients they serve."

Graves' appointment marks a significant step as ConcertAI expands its suite of AI-powered solutions to accelerate research and improve patient outcomes. His blend of commercial leadership, scientific understanding, and technological vision will be essential in driving the next phase of growth for the company's clinical solutions, ensuring they continue to make a real difference in cancer research and care worldwide.

About ConcertAI

ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.

Fonte: Business Wire